**Proteins** 

# **Batabulin**

Cat. No.: HY-13563 CAS No.: 195533-53-0 Molecular Formula:  $C_{13}H_7F_6NO_3S$ Molecular Weight: 371.26

Target: Microtubule/Tubulin; Apoptosis

Pathway: Cell Cycle/DNA Damage; Cytoskeleton; Apoptosis

Storage: Powder -20°C 3 years

> 4°C 2 years -80°C

In solvent 6 months

-20°C 1 month

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

Ethanol: 100 mg/mL (269.35 mM; Need ultrasonic) DMSO: 100 mg/mL (269.35 mM; Need ultrasonic)

|                              | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
| Preparing<br>Stock Solutions | 1 mM                          | 2.6935 mL | 13.4677 mL | 26.9353 mL |
|                              | 5 mM                          | 0.5387 mL | 2.6935 mL  | 5.3871 mL  |
|                              | 10 mM                         | 0.2694 mL | 1.3468 mL  | 2.6935 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description Batabulin (T138067) is an antitumor agent, which binds covalently and selectively to a subset of the  $\beta$ -tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death<sup>[1]</sup>.

IC<sub>50</sub> & Target β-tubulin<sup>[1]</sup>

### In Vitro

Batabulin (T138067; 30-300 nM; 24 hours; MCF7 cells) treatment shows approximately 25-30% tetraploid (4n) DNA content in cells, indicating an arrest at the  ${\rm G2/M}$  cell-cycle boundary  $^{[1]}$ .

Batabulin (T138067; 30-300 nM; 24-48 hours; MCF7 cells) treatment shows 25-30% apoptosis. After a 48-hr exposure to 100 nM Batabulin, approximately 50-80% of the cell population is undergoing apoptosis<sup>[1]</sup>.

Batabulin (T138067) binds covalently and selectively to a subset of the  $\beta$ -tubulin isotypes, thereby disrupting microtubule polymerization. Covalent modification occurs at a conserved Cys-239 shared by the  $\beta$ 1,  $\beta$ 2, and  $\beta$ 4 tubulin isotypes. Cells exposed to Batabulin become altered in shape, indicating a collapse of the cytoskeleton, and show an increase in chromosomal ploidy<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis<sup>[1]</sup>

| Cell Line:       | MCF7 cells  |  |
|------------------|---|--|
| Concentration:   | 30 nM, 100 nM and 300 nM                          |  |
| Incubation Time: | 24 hours  |  |
| Result:          | Showed an arrest at the G2/M cell-cycle boundary. |  |

## Apoptosis Analysis (1)

| Cell Line:       | MCF7 cells  |  |
|------------------|---|--|
| Concentration:   | 30 nM, 100 nM and 300 nM  |  |
| Incubation Time: | 24 hours or 48 hours  |  |
| Result:          | 25-30% of cells showed the reduced DNA content characteristic of apoptotic cells. |  |

## In Vivo

Batabulin (T138067; 40 mg/kg; intraperitoneal injection; once per week; on days 5, 12, and 19; male athymic nude mice) treatment impairs the growth of the drug-sensitive CCRF-CEM tumors [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| Animal Model:   | Male athymic nude mice (nu/nu) (6-8 week-old, 20-25 g) injected withCCRF-CEM cells <sup>[1]</sup> |  |
|-----------------|---|--|
| Dosage:         | 40 mg/kg  |  |
| Administration: | Intraperitoneal injection; once per week; on days 5, 12, and 19                                   |  |
| Result:         | Impaired the growth of the drug-sensitive CCRF-CEM tumors.  |  |

### **REFERENCES**

[1]. Shan B, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5686-91.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA